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Abstract
Background: Neurogenic bladder (NGB) dysfunction after spinal cord injury (SCI) is generally irreversible.
Preliminary animal and human studies have suggested that initiation of sacral neuromodulation (SNM) immediately
following SCI can prevent neurogenic detrusor overactivity and preserve bladder capacity and compliance. We
designed a multicenter randomized clinical trial to evaluate the effectiveness of early SNM after acute SCI.
Methods/Design: The scientific protocol comprises a multi-site, randomized, non-blinded clinical trial. Sixty acute,
acquired SCI patients (30 per arm) will be randomized within 12 weeks of injury. All participants will receive
standard care for NGB including anticholinergic medications and usual bladder management strategies. Those
randomized to intervention will undergo surgical implantation of the Medtronic PrimeAdvanced Surescan 97,702
Neurostimulator with bilateral tined leads along the S3 nerve root in a single-stage procedure. All patients will
undergo fluoroscopic urodynamic testing at study enrollment, 3 months, and 1-year post randomization. The
primary outcome will be changes in urodynamic maximum cystometric capacity at 1-year. After accounting for a
15% loss to follow-up, we expect 25 evaluable patients per arm (50 total), which will allow detection of a 38%
treatment effect. This corresponds to an 84 mL difference in bladder capacity (80% power at a 5% significance
level). Additional parameters will be assessed every 3 months with validated SCI-Quality of Life questionnaires and
3-day voiding diaries with pad-weight testing. Quantified secondary outcomes include: patient reported QoL,
number of daily catheterizations, incontinence episodes, average catheterization volume, detrusor compliance,
presence of urodynamic detrusor overactivity and important clinical outcomes including: hospitalizations, number
of symptomatic urinary tract infections, need for further interventions, and bowel and erectile function.
Discussion: This research protocol is multi-centered, drawing participants from large referral centers for SCI and has
the potential to increase options for bladder management after SCI and add to our knowledge about
neuroplasticity in the acute SCI patient.
Trial registration: ClinicalTrials.gov #NCT03083366 1/27/2017.
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Background
Urinary bladder dysfunction and incontinence have a
significant clinical, physical, and quality of life (QoL)
burden in patients with spinal cord injury (SCI). Con-
temporary studies report bladder problems are the sec-
ond leading reason SCI patients seek medical care.
Almost 80% of SCI patients report some degree of blad-
der dysfunction within 1 year of injury and 42% are hos-
pitalized for urinary problems every year [1–4]. Renal
failure and urinary sepsis historically were the major
causes of death in SCI patients after recovery from the
initial injury [5]. Advances in urologic care, specifically
the introduction of clean intermittent catheterization
(CIC) in the 1970’s revolutionized the care of SCI patients
[6, 7]. However, there is a significant inconvenience, po-
tential dependence on others, and often continued leakage
that leads to patient non-compliance and discontinuation
of CIC [4, 8, 9]. The currently established goals of neuro-
genic bladder (NGB) management include; prevention of
renal insufficiency or failure by keeping bladder pressures
low, preservation of urinary continence, and optimization
of QoL. Current available treatments including pharmaco-
logic therapy, injection of botulinum toxin, and surgical
bladder augmentation or urinary diversion all address
NGB physiology at the bladder level rather than the
neurologic injury leading to NGB.
Largely, NGB cannot be reversed and prevention of
the development of some of the worst aspects of NGB
such as poor compliance, high intravesical filling pres-
sures, and spasticity by trying to address the neurologic
cause of these sequelae is a unique research approach.
Over the past 20 years sacral neuromodulation (SNM)
has become an established treatment for refractory urin-
ary urge incontinence, urinary frequency/urgency syn-
drome, non-obstructive idiopathic urinary retention and
chronic fecal incontinence [10–13]. The surgical proced-
ure is minimally invasive and has few risks. Recent
animal and human pilot data suggest that SNM imple-
mented in the acute setting after SCI may preserve blad-
der compliance, bladder volume, and reduce urinary
tract infections [14–16].
Based on this encouraging preliminary data, we de-
signed a prospective, randomized, multicenter clinical
trial to assess the efficacy and safety of SNM for treat-
ing neurogenic bladder dysfunction in patients with
spinal cord injuries. The study hypothesizes that sacral
neuromodulation, initiated during the acute phase fol-
lowing spinal cord injury, can decrease bladder spasti-
city preserving bladder compliance, bladder volume,
and low bladder filling pressures. This will result in im-
provements in both objective quantifiable clinical
outcomes, as well as subjective patient reported quality
of life compared with standard neurogenic bladder
management.
Methods and design
Study design
Patients will be randomized to standard neurogenic blad-
der management or standard management plus sacral
neuromodulation (via S3 nerve root stimulation) in a par-
allel non-blinded fashion with the intent to demonstrate
the superiority of sacral neuromodulation plus standard
management over standard management alone. Patients
randomized to the intervention arm, will undergo im-
plantation of the PrimeAdvanced Surescan 97702 Neuro-
stimulator (Medtronic, Minneapolis, MN) with bilateral
tined leads within 12 weeks of spinal cord injury.
Study locations
The study will take place at the Universities of Michigan,
Minnesota, and Utah. All three of these sites are large vol-
ume academic hospitals that see a high volume of patients
with SCI and are associated with acute rehabilitation cen-
ters that treat SCI immediately after hospitalization from
injury.
Study population and recruitment
Patients will initially be identified with the assistance of
our colleagues in either Physical Medicine & Rehabilita-
tion or Neurosurgery according to the inclusion and ex-
clusion criteria in Table 1. All consecutive patients will
be eligible for screening and approached for enrollment.
Investigations
Sixty patients will be enrolled and randomized (30 per
arm). A timeline and an overview of the procedures and
diagnostic studies that will occur during the course of
the study are shown in Fig. 1. The PrimeAdvanced Sur-
escan 97702 Neurostimulator (Medtronic, Minneapolis,
MN, USA) with bilateral tined leads will be implanted in
patients randomized to the intervention arm using a
standard surgical technique. Because the study hypoth-
esis dictates early stimulation of the sacral nerve roots
with a primary outcome evaluated 1 year post implant,
the quadripolar tined leads and pulse generator will be
placed in the same procedure. Food and drug adminis-
tration (FDA) approved programming parameters for
the InterStim II system will be utilized in this study.
All patients will receive usual standard of care bladder
management for neurogenic bladder. Specifically, standard
treatment entails the following: [1] clean intermittent
catheterization (CIC) at regular timed intervals, [2] treat-
ment with anticholinergic medicine or botulinum toxin as
indicated to increase bladder compliance, decrease urinary
leakage, and lower bladder pressures to prevent renal
damage, [3] routine follow up in the urology and physical
medicine and rehabilitation clinic [17].
At enrollment, all participants will complete the fol-
lowing: [1] standardized 3-day voiding diary to annotate
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the catheterization time, amount and time of fluid in-
take, and incontinence events, [2] 24 h pad weight test,
[3] 3-day bowel diary to quantify baseline bowel habits,
[4] inventory of current medications, [5] the Neurogenic
Bladder Symptom Score (NBSS), [6] Spinal Cord Injury
Quality of Life questionnaire (SCI-QoL) Bladder Man-
agement Difficulties, [7] SCI-QoL Bladder Complica-
tions, [7] the Neurogenic Bowel Dysfunction Score, [8] a
non-validated questionnaire about autonomic dysreflexia
impact, [9] Sexual Health Inventory for Men (SHIM),
and [18] baseline urodynamic testing. Repeat measure-
ments, other than urodynamic testing, will be obtained
during clinic visits at 3, 6, 9, and 12 months after enroll-
ment. For patients randomized to the intervention arm,
urodynamic testing will be completed less than 2 weeks
before implantation of the device. Urodynamic testing will
be repeated at 3 months and then again at 12 months.
At each time point, a retrospective review since the
prior time point will be performed in order to capture
major events such as urinary tract infection (UTI), hospi-
talizations, additional surgery, as well as additional sub-
jective data. Those additional subjective data will include:
(1) current usage of anti-cholinergic medications and/or
botulinum toxin treatment (2) bowel program including
use of medication and mechanical aids (i.e. digital stimula-
tion, enemas, etc.), (3) use of medications for sexual func-
tion, (4) symptomatic UTIs requiring antibiotic treatment,
(4) complications attributable to the device, (5) need for
revision of device or leads. A renal ultrasound will be ob-
tained at the end of 12 months to evaluate for the devel-
opment of hydronephrosis. This will be compared with
baseline CT or US imaging obtained during their initial
trauma evaluation. Serum creatinine as an estimate of
renal function will be collected annually. Variables to be
collected during the course of the study and timeline for
collecting them is shown in Table 2.
Safety
The study safety monitoring committee will consist of a
study investigator, a non-investigator urologist familiar
with SNM, and an independent safety monitor (ISM) (a
non-investigator familiar with randomized trial design).
The safety committee will meet semi-annually and the
ISM will have the authority to halt the study. Videos of
the 1st procedures and two other randomly assigned
procedures of the 10 expected from each center will be
produced and viewed by the safety monitoring commit-
tee to assure consistency in placement of the SNM de-
vice. The following criteria will be used to evaluate the
surgical technique used for the procedures.
Video evaluation criteria for device implantation:
 Maintenance of sterile procedure and use of a
double prep with an iodine skin protective cover.
 Placement of electrodes appropriately using
fluoroscopy in the S3 foramen.
 Adequate testing for motor response indicating close
proximity of the nerve and appropriate placement in
the S3 foramen.
 Correctly attaching electrodes to the IPG device and
tunneling of electrodes.
 Appropriate closure of all incisions in a manner
consistent with preventing erosions of the electrodes
or generator.
Reportable safety concerns will be any of the following:
(1) device infection requiring antibiotics or removal (signifi-
cant rates triggering a full review and report will be greater
than 5% infection rate), (2) revision of device and reason
for revision accounting for surgical, device, or patient fac-
tors (significant rates triggering a full review of the device
use will be greater than a 30% revision rate over the course
of study), (3) autonomic dysreflexia rates in patients within
both arms of the study as assessed by the autonomic dysre-
flexia specific questionnaires and any autonomic dysre-
flexia, which causes patients to turn off the device for more
than a few minutes, not use the device as intended, or are
the reason for explantation, (4) the need for removal of the
Table 1 Study inclusion and exclusion criteria
Inclusion criteria
Age > 18 years
Ability to implant device less than 12 weeks post-SCI
Presence of acute SCI at or above T12
ASIA scale A or B
Expectation to perform CIC personally or have caretaker perform CIC
Medically stable to discharge to a rehab setting
Exclusion criteria
Inability to perform CIC or have caregiver perform it
Pre-existing SCI
Pre-existing progressive neurological disorder
Autonomic dysreflexia
Prior sacral back surgery
Posterior pelvic fracture with distortion of the sacroiliac joint
Prior urethral sphincter or bladder dysfunction
Chronic urinary tract infections prior to SCI
Pregnancy at the time of enrollment
Presence of coagulation disorder or need for anticoagulation that
they connot be stopped temporarily for procedure
Any significant co-morbidity or illness that would preclude their
participation or increase the risk to them having a surgical procedure
Active untreated infection
Traumatic injury to the genitourinary system
Prior pelvic radiation, bladder cancer or other surgical procedure to
the bladder that would effect baseline bladder physiology
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device for erosion or pressure ulcers, (5) the need to re-
move the device due to the need for MRI imaging, (6) sur-
gical complications within 6 weeks as classified by the
Clavien-Dindo classification. Any events in category 1–6
will be reviewed by the study investigators as a whole dur-
ing a semi-annual report from the safety committee. Event
rates 1–6 will be disclosed to participants in the study dur-
ing the consent process after they have been reviewed by
the safety committee and investigators.
Safety committee will include reports to the FDA, in-
stitutional IRB’s, and to the funding agency (the Depart-
ment of Defense) at 6 month intervals or as specified by
the rules of each organization. A written report of all ad-
verse events will be created every 3 months and a log
maintained with study documents.
An interim analysis will be conducted at 50% enrollment
(N = 26 after loss to follow-up, 13 patients per arm) accrual,
and the decision to stop early will be governed by a
significance level of 0.003. The ISM decision to stop early
will be guided both by interim results and clinical judg-
ment, especially in the context of emerging, relevant
literature.
Study device
The PrimeAdvanced Surescan 97702 Neurostimulator is
an implantable device marketed by Medtronic (Minneap-
olis, MN, USA) for use in the United States. It is FDA ap-
proved for spinal cord stimulation rather than sacral
nerve root stimulation, which is the intention of this
study, however, it is conceptually and functionally, similar
to the InterStim II Model 3058 neurostimulator, which is
FDA approved for sacral neurostimulation in the United
States. Importantly, unlike the InterStim II, the PrimeAd-
vanced has the ability to accommodate and simultan-
eously stimulate bilateral leads. All the preliminary studies
in acute spinal cord injury have utilized bilateral sacral
Fig. 1 Summary of study protocol. Spinal cord injury (SCI), Sacral neuromodulation (SNM), Neurogenic bladder (NGB), S3 Sacral nerve root (S3),
Quality of life (QoL)
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stimulation, which we believe offers a certain amount of
redundancy defending against failure due to lead migra-
tion or malfunction and possibly increased efficacy.
Implantation is usually accomplished via a two-step
process involving a placement of the permanent quadripo-
lar electrode alongside the S3 nerve root under local or
general anesthesia. This permanent lead is controlled by a
temporary external programming device for 7–14 days. If
greater than 50% improvement in clinical symptoms over
that test period, the internal pulse generator (IPG) is im-
planted subcutaneously under during a second surgical
procedure. Because the study hypothesis dictates early
stimulation of the sacral nerve roots with a primary out-
come evaluated 1 year post implant, the quadripolar elec-
trical lead and IPG will be placed in the same procedure.
This will avoid delay in stimulation of the sacral nerves
during the critical window for preventing adverse neuro-
plastic changes. Patients will be mostly insensate due to
their SCI or being under general anesthesia for the proced-
ure. Therefore, to confirm intraoperative placement we will
rely upon expected motor responses associated with S3
stimulation (anal bellows and toe flexion). If correct motor
responses cannot be elicited intraoperatively than the pa-
tients will not undergo implantation and will be included in
the randomized arm but in an ‘intention-to-treat’ manner.
FDA approved programming parameters for the InterStim
II system will be utilized in this study as follows. The device
will provide continuous stimulation (i.e. always on) without
discrete treatment periods. The PrimeAdvanced Surescan
IPG is capable of generating a maximum voltage of 10.5 V,
2 V higher than the InterStim II system, however, it will be
programed to function within the normal InterStim II
Table 2 Primary and secondary outcome variables. UDS (urodynamic study), NBSS (Neurogenic Bladder Symptom Score), SCI-QoL
(spinal cord injury quality of life measurement system bladder management difficulties and bladder complications), SHIM (sexual
health inventory for men)
Collection method Time points (month) Variable type Analyzed At
Urodynamic parameters – aim 1
Primary
Maximum cystometric capacity UDS 0,12 m Continuous 12 m
Secondary
Maximum cystometric at 3 months UDS 0,3 m Continuous 3 m
Bladder compliance UDS 0,3,12 m Continuous 3 m, 12 m
Presence of detrusor overactivity UDS 0,3,12 m Binary 3 m, 12 m
Volume & pressure at first detrusor contraction UDS 0,3,12 m Continuous 3 m, 12 m
Quality of Life – Aim 2
Primary
Difference in mean NBSS, SCI-QoL questionnaires Questionnaire 3,6,9,12 m Continuous 3,6,9,12 m
Secondary
Daily number of catheterizations, Bladder diary 3,6,9,12 m Continuous 3,6,9,12 m
Average catheterization volume, Bladder diary 3,6,9,12 m Continuous 3,6,9,12 m
Urinary incontinence episodes per day Bladder diary 3,6,9,12 m Continuous 3,6,9,12 m
24 h pad weight test 24 h pad 3,6,9,12 m Continuous 3,6,9,12 m
Clinical – Aim 3
Primary
# of UTIs requiring antibiotics Chart review 12 m Continuous 12 m
Secondary
Development of hydronephrosis Renal ultrasound 12 m Categorical 12 m
Need for anticholinergic medication Chart review 12 m Binary 12 m
Botulinum toxin injection Chart review event Binary 12 m
Need for device revision Chart review event Binary 12 m
Device explanation Chart review event Binary 12 m
Use of medications / mechanical bowel stimulation Chart review event Continuous 12 m
SHIM Chart review event Continuous 12 m
Erectile dysfunction medications Chart review event Continuous 12 m
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system parameters (maximum 8.5 V). Additionally, it will be
programed to use the same stimulation pulsewidth
(210 msec) and frequency (14 Hz) as the InterStim II sys-
tem. The area under the stimulation curve will be the same
or less than intended by the InterStim II parameters.
Each patient will be evaluated intraoperatively as is
standard clinical practice to select stimulation parameters
that result in typical, consistent physiological responses
(e.g. anal bellows and first toe flexion). The default 14 Hz
frequency will be maintained. The electrode with the low-
est amplitude stimulation as a proxy for the most closely
placed electrode to the S3 nerve. This electrode will be
trialed first. The stimulation amplitude will be set at 0.7 V
per protocol as was utilized in the one prior bilateral SNM
study in acute SCI. Note: If the subject has S3 sensation
(incomplete SCI), the amplitude will be set 0.1 V lower
than the level of sensation. In such sensate patients, each
lead will be programmed individually and then both leads
will be activated simultaneously to determine whether fur-
ther amplitude reduction is needed. These parameters will
be set during the initial programming session and will re-
main constant for the duration of the study. All study cen-
ters will utilize the same protocol.
Statistical analyses and outcomes
Sample size calculations for this study were based on the
preliminary research by Sievert et al., and a feasibility of en-
rolling 30 patients per arm within the study period [16].
After accounting for a 15% loss to follow-up we expect 25
evaluable patients per arm. Using thresholds for study
power of 80% (5% significance level) we would detect a 38%
treatment effect (84 mL difference in bladder capacity).
Aim 1: To determine the effect of sacral neuromodulation
on urodynamic parameters in the setting of acute spinal
cord injury
The efficacy of SNM on the following urodynamic parame-
ters will be evaluated at 3 months and 1 year post-injury: (1)
maximum cystometric capacity, (2) bladder compliance, (3)
presence of detrusor overactivity, and (4) volume and pres-
sure for first detrusor contraction. Maximum cystometric
capacity at 1 year is the primary outcome, and it will be
compared between SNM and control arms using restricted
maximum likelihood estimation under a linear mixed model
controlling for institution [19]. Both an intention to treat
and per-protocol analysis will be performed to account for
any patients who were randomized to the intervention arm,
but were unable to undergo placement of the device due to
poor motor response intraoperatively.
Aim 2: To assess the impact of sacral neuromodulation on
patient-reported quality of life after acute spinal cord injury
Patient-reported QoL will be assessed using the Neuro-
genic Bladder Symptom Score (NBSS) and the two bladder
specific item banks from the spinal cord injury quality of
life measurement system (SCI-QoL) Bladder Management
Difficulties and Bladder Complications. We will use a simi-
lar linear mixed model framework as described in Aim 1 to
compare the mean questionnaire scores at each follow-up
assessment between the intervention (SNM) and control
arms. The primary outcome will be the difference in mean
questionnaire scores. Secondary outcomes will include daily
number of catheterizations, average catheterization vol-
ume, and episodes of incontinence per day will be com-
pared between groups. The primary efficacy will be
evaluated at 1 year between the randomized groups.
Secondary contrasts will evaluate intermediate treat-
ment effects at earlier time points, and on average
across all time points.
Aim 3: To examine the impact of sacral neuromodulation
on quantifiable clinical outcomes
Patients will be followed longitudinally during the study
period and assessed for the following: (1) number of
symptomatic UTIs per year, (2) need for anti-cholinergic
medications and/or botulinum toxin treatment, (3) com-
plications attributable to the device, (4) need for revision
of device or leads due to lead migration or failure, (5)
development of hydronephrosis, (6) the need for medi-
cations and or mechanical aids (i.e. digital stimulation,
enemas, etc.) for bowel program (7) SHIM scores, and
(8) use of medications for erectile function. Our primary
outcome will be the rate of symptomatic UTIs requiring
antibiotic treatment over the 12-month study period.
UTIs and many of our secondary complications can be
experienced multiple times throughout the year. As a re-
sult, we will use a frailty model to handle complications
that are potentially recurring events [20]. This method
allows for heterogeneity among the evaluable subjects in
terms of their differences in complication risk, as it is
likely that some subjects will be more prone to UTIs
(and other complications) than others. Events such as
the use of anticholinergic medicines for control of de-
trusor overactivity are simply yes/no indicators during the
annual period, and are thus more meaningfully modeled
in the typical Cox regression framework for analyzing sin-
gle rather than recurrent events. Again, all analyses will
control for institution.
Ethics and dissemination
An investigational device exemption (G160136/A002)
was obtained from the FDA. A centralized IRB (based at
the University of Utah) will approve a data and safety
monitoring plan to the risks and complexity of this trial.
Approval from the USAMRC ORP Human Research
Protection Office has also been granted. This trial will
be performed in accordance with the guidelines for
Good Clinical Practice in Clinical Trials. Handling of all
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personal data will strictly comply with the Health Insur-
ance Portability and Accountability Act. The trial has
been registered at clinicaltrials.gov (https://clinicaltrials
.gov/ct2/show/NCT03083366).
Discussion
Sacral neuromodulation has a very well established track
record in the treatment of patients with non-neurogenic
urinary and fecal dysfunction. In the US, the InterStim
Therapy System (Medtronic, Minneapolis, MN, USA) has
been FDA approved for use in idiopathic overactive blad-
der since 1997, urinary frequency/urgency syndrome and
non-obstructive idiopathic urinary retention since 1999,
and for chronic fecal incontinence since 2011 [21–24]. Ef-
ficacy is well established for all three uses. In idiopathic
overactive bladder, SNM achieves sustained therapeutic
success in 85% of patients with a greater than 60% reduc-
tion in leaks per day. From a quality of life standpoint,
80% of subjects report significant improvement in their
urinary symptoms [23]. Similar improvements with SNM
are noted when treating chronic fecal incontinence, with
86% of patients achieving therapeutic success [25].
Once changes in the neurological control of the blad-
der have occurred following SCI they are in most cases
irreversible. As a result, treatments must be directed at
the local muscle level in order to control the high blad-
der pressures, incontinence and other symptoms. Conse-
quently, the majority of research into the effects of
spinal cord injury on the urinary bladder has focused on
patients with well-established chronic neurogenic blad-
der physiology. Interventions during the acute phase of
SCI aimed at preventing the development of, or reducing
the symptoms of NGB, has not been extensively studied.
SNM implemented during the acute phase of SCI has
good theoretical and experimental support in both ani-
mal and human clinical studies. In an animal model of
complete spinal cord injury, Shi et al. demonstrated that
SNM, could reduce peak bladder pressures and uninhib-
ited detrusor contractions during bladder filling [14]. In
vitro on a tissue level, in isometric relaxation experi-
ments complete spinal cord transection caused a de-
crease in β-adrenergic relaxation responses which was
shown to be muted by SNM in an animal model [15].
In humans, a pilot feasibility study has also demonstrated
efficacy of SNM in the acute phase of SCI. Sixteen patients
with traumatic complete SCI were enrolled during the
acute bladder-areflexia phase [16]. Ten of these patients
were implanted with bilateral sacral neuromodulators in a
non-randomized fashion less than 3 months after their ini-
tial spinal cord injury. Six patients who met inclusion cri-
teria, but did not wish to undergo treatment were used as
controls. At 1 year follow-up, urodynamic studies showed
an increased capacity (582 mL vs 294 mL), improved com-
pliance and end filling pressures. The patients who
underwent SNM had fewer UTIs (0.5/yr. vs. 3.8/yr) and
hospital admissions. Other benefits of SNM included elim-
ination of incontinence, in fact, none of the patients in the
SNM group experienced incontinence, compared to 100%
of the control group. Additional evidence for improvement
in bladder pressures was the decreased need for
anti-cholinergic medications (20% in the SNM group vs.
100% in controls).
This research protocol is multi-centered, drawing par-
ticipants from large academic referral centers for SCI
and has the potential to increase options for bladder
management after SCI and add to our knowledge about
neuroplasticity in the acute SCI patient.
Trial status
The trial is in the recruiting phase at the time of manu-
script submission.
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